EJNMMI Radiopharmacy and Chemistry (Mar 2023)

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

  • Oliver C. Kiss,
  • Peter J. H. Scott,
  • Martin Behe,
  • Ivan Penuelas,
  • Jan Passchier,
  • Ana Rey,
  • Marianne Patt,
  • Silvio Aime,
  • Amir Jalilian,
  • Peter Laverman,
  • Zhen Cheng,
  • Alain Faivre Chauvet,
  • Jonathan Engle,
  • Frederik Cleeren,
  • Hua Zhu,
  • Johnny Vercouillie,
  • Michael van Dam,
  • Ming Rong Zhang,
  • Lars Perk,
  • Benjamin Guillet,
  • Francisco Alves

DOI
https://doi.org/10.1186/s41181-023-00192-5
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Main Body This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals. Conclusion Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for 11C and 18F, the importance of choosing the proper chelator for a given radioactive metal ion, implications of total body PET on use of radiopharmaceuticals, legislation issues and radionuclide therapy including the emerging role of 161Tb.

Keywords